PURPOSE: In an effort to promote local control and improve quality of life in patients with recurrent colorectal cancer, a multimodality approach has been used. METHODS AND MATERIALS: Twenty-seven patients were treated with moderate doses of pre/postoperative radiotherapy with/without simultaneous systemic chemotherapy, surgical re-resection and IORT electron boost over areas at high risk for local recurrence. RESULTS: The 2-year actuarial disease-free and local relapse-free survival for the entire group were 14% and 26%, respectively. The most important factor predicting a favorable outcome was the radicality of surgical procedure. The determinate local control rate and the actuarial 2-year local relapse-free, and disease-free survival for patients undergoing complete resections were 50%, 56%, and 34%, respectively, whereas for patients undergoing partial resections these figures were 16%, 13%, and 6%. The radicality of surgical procedure was influenced by both tumoral size and previous treatment with irradiation. Complete resection rate was higher in patients with tumors less than 5 cm vs. more than 5 cm (40% vs. 22%), and in patients without previous radiotherapy versus those with previous radiotherapy (40% vs. 28%). Distant metastasis rate was high (41%). The most significant toxicities attributable to the whole treatment protocol were enteritis (37%), hydronephrosis (30%), and pelvic neuropathy (52%). CONCLUSION: Currently, our policy is to recommend IORT in patients with "favorable factors" such as: absence of previous pelvic radiotherapy, single previous surgical procedure, and complete resections.
PURPOSE: In an effort to promote local control and improve quality of life in patients with recurrent colorectal cancer, a multimodality approach has been used. METHODS AND MATERIALS: Twenty-seven patients were treated with moderate doses of pre/postoperative radiotherapy with/without simultaneous systemic chemotherapy, surgical re-resection and IORT electron boost over areas at high risk for local recurrence. RESULTS: The 2-year actuarial disease-free and local relapse-free survival for the entire group were 14% and 26%, respectively. The most important factor predicting a favorable outcome was the radicality of surgical procedure. The determinate local control rate and the actuarial 2-year local relapse-free, and disease-free survival for patients undergoing complete resections were 50%, 56%, and 34%, respectively, whereas for patients undergoing partial resections these figures were 16%, 13%, and 6%. The radicality of surgical procedure was influenced by both tumoral size and previous treatment with irradiation. Complete resection rate was higher in patients with tumors less than 5 cm vs. more than 5 cm (40% vs. 22%), and in patients without previous radiotherapy versus those with previous radiotherapy (40% vs. 28%). Distant metastasis rate was high (41%). The most significant toxicities attributable to the whole treatment protocol were enteritis (37%), hydronephrosis (30%), and pelvic neuropathy (52%). CONCLUSION: Currently, our policy is to recommend IORT in patients with "favorable factors" such as: absence of previous pelvic radiotherapy, single previous surgical procedure, and complete resections.
Authors: L L Gunderson; D M Nagorney; J A Martenson; J H Donohue; G R Garton; H Nelson; J Fieck Journal: World J Surg Date: 1995 Mar-Apr Impact factor: 3.352
Authors: Jun Jie Wang; Hui Shu Yuan; Jin Na Li; Wei Juan Jiang; Yu Liang Jiang; Su Qing Tian Journal: Int J Colorectal Dis Date: 2008-12-16 Impact factor: 2.571
Authors: Andre A Konski; W Warren Suh; Joseph M Herman; A William Blackstock; Theodore S Hong; Matthew M Poggi; Miguel Rodriguez-Bigas; William Small; Charles R Thomas; Jennifer Zook Journal: Gastrointest Cancer Res Date: 2012-01
Authors: Susan Guo; Chandana A Reddy; Matthew Kolar; Neil Woody; Arul Mahadevan; F Christopher Deibel; David W Dietz; Feza H Remzi; John H Suh Journal: Radiat Oncol Date: 2012-07-20 Impact factor: 3.481
Authors: Falk Roeder; Joerg-Michael Goetz; Gregor Habl; Marc Bischof; Robert Krempien; Markus W Buechler; Frank W Hensley; Peter E Huber; Juergen Weitz; Juergen Debus Journal: BMC Cancer Date: 2012-12-11 Impact factor: 4.430
Authors: Felipe A Calvo; Claudio V Sole; Harm J Rutten; Wim J Dries; Miguel A Lozano; Mauricio Cambeiro; Philip Poortmans; Luis González-Bayón Journal: Clin Transl Radiat Oncol Date: 2020-06-17